Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00002315 · ClinicalTrials.gov registry record · Phase 3
A Comparison of 882C87 Versus Acyclovir in the Treatment of Herpes Zoster in Patients With Weakened Immune Systems
A Phase 3 study, sponsored by Glaxo Wellcome.
- Completed
- Registry status
- Phase 3
- Development phase
- 400
- Enrollment target
NCT00002315 is a Phase 3 study that has completed, run by Glaxo Wellcome. The registered enrollment target is 400 participants.
The verdict
NCT00002315, a Phase 3 study, has completed, sponsored by Glaxo Wellcome.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 400 participants
- Enrollment target
Study Summary
To determine the efficacy of oral 882C87 compared with oral acyclovir in the treatment of localized herpes zoster in immunocompromised patients. To assess the safety and tolerance of oral 882C87 in immunocompromised patients.
Interventions
- DRUG Acyclovir
- DRUG Netivudine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 400 participants |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00002315
The ClinicalTrials.gov registry entry for NCT00002315 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 400 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Glaxo Wellcome, which has 65 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Acyclovir is the first listed.
NCT00002315 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00002315 about?
NCT00002315 is a clinical study titled "A Comparison of 882C87 Versus Acyclovir in the Treatment of Herpes Zoster in Patients With Weakened Immune Systems". To determine the efficacy of oral 882C87 compared with oral acyclovir in the treatment of localized herpes zoster in immunocompromised patients. To assess the safety and tolerance of oral 882C87 in immunocompromised patients.
What is the current status of trial NCT00002315?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 400 participants.
What interventions are being tested in trial NCT00002315?
The interventions under investigation include: Acyclovir (DRUG), Netivudine (DRUG).
Who is sponsoring clinical trial NCT00002315?
This trial is sponsored by Glaxo Wellcome, which has 65 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.